Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DR 01

Next Previous
Drug Profile

DR 01

Alternative Names: DR-01; DR-01 program

Latest Information Update: 28 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dren Bio
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily D modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Large granular lymphocytic leukaemia; Lymphoma
  • Phase I Alopecia areata; Unspecified; Vitiligo
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Feb 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (IV)
  • 06 Dec 2025 Initial efficacy, adverse event and pharmacodynamics data from a phase I trial in Large granular lymphocytic leukaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Efficacy, safety, pharmacodynamics and pharmacokinetics data from a phase I/II trial in Large granular lymphocytic leukaemia and Lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top